Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

PHASE3CompletedINTERVENTIONAL
Enrollment

499

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

April 30, 2012

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Placebo

Placebo tablets matching BI 10773 low dose

DRUG

BI 10773

BI 10773 tablets once daily

DRUG

Placebo

Placebo tablets matching BI 10773 high dose

DRUG

Placebo

Placebo tablets matching BI 10773 high dose

DRUG

Placebo

Placebo tablets matching BI 10773 high dose

DRUG

BI 10773

BI 10773 tablets once daily

Trial Locations (68)

Unknown

1245.19.10056 Boehringer Ingelheim Investigational Site, Muscle Shoals

1245.19.10162 Boehringer Ingelheim Investigational Site, Glendale

1245.19.10161 Boehringer Ingelheim Investigational Site, Phoenix

1245.19.10046 Boehringer Ingelheim Investigational Site, Tempe

1245.19.10070 Boehringer Ingelheim Investigational Site, Irvine

1245.19.10047 Boehringer Ingelheim Investigational Site, La Mesa

1245.19.10149 Boehringer Ingelheim Investigational Site, Rancho Cucamonga

1245.19.10163 Boehringer Ingelheim Investigational Site, Riverside

1245.19.10131 Boehringer Ingelheim Investigational Site, West Hills

1245.19.10141 Boehringer Ingelheim Investigational Site, Milford

1245.19.10133 Boehringer Ingelheim Investigational Site, Jupiter

1245.19.10085 Boehringer Ingelheim Investigational Site, Plantation

1245.19.10077 Boehringer Ingelheim Investigational Site, Perry

1245.19.10014 Boehringer Ingelheim Investigational Site, Dubuque

1245.19.10160 Boehringer Ingelheim Investigational Site, Essex

1245.19.10003 Boehringer Ingelheim Investigational Site, Dearborn

1245.19.10059 Boehringer Ingelheim Investigational Site, New Hyde Park

1245.19.10123 Boehringer Ingelheim Investigational Site, Smithtown

1245.19.10071 Boehringer Ingelheim Investigational Site, Asheboro

1245.19.10086 Boehringer Ingelheim Investigational Site, Salisbury

1245.19.10008 Boehringer Ingelheim Investigational Site, Marion

1245.19.10033 Boehringer Ingelheim Investigational Site, Chattanooga

1245.19.10112 Boehringer Ingelheim Investigational Site, Memphis

1245.19.10002 Boehringer Ingelheim Investigational Site, Norfolk

1245.19.20047 Boehringer Ingelheim Investigational Site, Vancouver

1245.19.20062 Boehringer Ingelheim Investigational Site, Vancouver

1245.19.20012 G.A. Research Associates Ltd., Moncton

1245.19.20031 Boehringer Ingelheim Investigational Site, St. John's

1245.19.20057 Boehringer Ingelheim Investigational Site, Brampton

1245.19.20059 Boehringer Ingelheim Investigational Site, Fort Erie

1245.19.20060 Boehringer Ingelheim Investigational Site, London

1245.19.20009 Boehringer Ingelheim Investigational Site, Newmarket

1245.19.20034 Boehringer Ingelheim Investigational Site, Sarnia

1245.19.20058 Boehringer Ingelheim Investigational Site, Saint Romuald

1245.19.20041 Boehringer Ingelheim Investigational Site, Saskatoon

1245.19.30002 Boehringer Ingelheim Investigational Site, Athens

1245.19.30001 Boehringer Ingelheim Investigational Site, Nikaia

1245.19.30004 Boehringer Ingelheim Investigational Site, Thessaloniki

1245.19.91005 Boehringer Ingelheim Investigational Site, Bangalore

1245.19.91006 Boehringer Ingelheim Investigational Site, Bangalore

1245.19.91008 Boehringer Ingelheim Investigational Site, Bangalore

1245.19.91003 Boehringer Ingelheim Investigational Site, Belagavi

1245.19.91004 Boehringer Ingelheim Investigational Site, Chennai

1245.19.91009 Boehringer Ingelheim Investigational Site, Chennai

1245.19.91001 Boehringer Ingelheim Investigational Site, Coimbatore

1245.19.91015 Boehringer Ingelheim Investigational Site, Kalaburagi

1245.19.91011 Boehringer Ingelheim Investigational Site, Kartanaka

1245.19.91002 Boehringer Ingelheim Investigational Site, Mumbai

1245.19.91007 Boehringer Ingelheim Investigational Site, Mumbai, Maharastra

1245.19.91017 Boehringer Ingelheim Investigational Site, Mysore

1245.19.91010 Boehringer Ingelheim Investigational Site, Nagpur

1245.19.91012 Boehringer Ingelheim Investigational Site, New Delhi

1245.19.91013 Boehringer Ingelheim Investigational Site, Patna

1245.19.91014 Boehringer Ingelheim Investigational Site, Pune

1245.19.91016 Boehringer Ingelheim Investigational Site, Pune

1245.19.63002 Boehringer Ingelheim Investigational Site, Cebu City, N/A, Philippines

1245.19.63003 Boehringer Ingelheim Investigational Site, Davao City, N/A, Philippines

1245.19.63004 Boehringer Ingelheim Investigational Site, Manila, Philippines

1245.19.63005 Boehringer Ingelheim Investigational Site, Pasig City, Philippines

1245.19.63001 Boehringer Ingelheim Investigational Site, San Juan City, Philippines

1245.19.66003 Boehringer Ingelheim Investigational Site, Saimai

1245.19.66004 Boehringer Ingelheim Investigational Site, Udon Thani, Thailand

1245.19.75002 Boehringer Ingelheim Investigational Site, Dnipro

1245.19.75001 Boehringer Ingelheim Investigational Site, Kharkiv

1245.19.75005 Boehringer Ingelheim Investigational Site, Kiev

1245.19.75006 Boehringer Ingelheim Investigational Site, Lviv

1245.19.75004 Boehringer Ingelheim Investigational Site, Vinnitsa

1245.19.75003 Boehringer Ingelheim Investigational Site, Vinnytsia

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY